DK167013B1 - 4-oxo-6-aminomethyl-quinazolinderivater,fremgangsmaade til fremstilling deraf, farmaceutiske midler indeholdende disse samt anvendelse af disse til fremstilling af laegemidler til behandling af tumorer - Google Patents

4-oxo-6-aminomethyl-quinazolinderivater,fremgangsmaade til fremstilling deraf, farmaceutiske midler indeholdende disse samt anvendelse af disse til fremstilling af laegemidler til behandling af tumorer Download PDF

Info

Publication number: DK167013B1
Authority: DK; Denmark
Prior art keywords: hydrogen; methyl; prop; ynyl; group
Prior art date: 1987-03-25

Application number

DK168488A

Other languages

Danish (da)

English (en)

Other versions

DK168488D0 (da

DK168488A (da

Inventor

Leslie Richard Hughes

Original Assignee

Ici Plc

Nat Res Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-03-25

Filing date

1988-03-25

Publication date

1993-08-16

1988-03-25 Application filed by Ici Plc, Nat Res Dev filed Critical Ici Plc

1988-03-25 Publication of DK168488D0 publication Critical patent/DK168488D0/da

1988-09-26 Publication of DK168488A publication Critical patent/DK168488A/da

1993-08-16 Application granted granted Critical

1993-08-16 Publication of DK167013B1 publication Critical patent/DK167013B1/da

Links

238000011282 treatment Methods 0.000 title claims description 8
238000004519 manufacturing process Methods 0.000 title claims description 5
239000008177 pharmaceutical agent Substances 0.000 title claims description 5
GXIWDAZXYHOCMK-UHFFFAOYSA-N 6-(aminomethyl)-1h-quinazolin-4-one Chemical class N1C=NC(=O)C2=CC(CN)=CC=C21 GXIWDAZXYHOCMK-UHFFFAOYSA-N 0.000 title claims description 4
238000000034 method Methods 0.000 title description 24
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 82
239000001257 hydrogen Substances 0.000 claims abstract description 72
150000002431 hydrogen Chemical class 0.000 claims abstract description 41
150000001875 compounds Chemical class 0.000 claims abstract description 34
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 31
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 21
125000000217 alkyl group Chemical group 0.000 claims abstract description 16
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 16
150000002148 esters Chemical class 0.000 claims abstract description 14
150000003839 salts Chemical class 0.000 claims abstract description 12
125000003545 alkoxy group Chemical group 0.000 claims abstract description 7
125000003342 alkenyl group Chemical group 0.000 claims abstract description 6
125000000304 alkynyl group Chemical group 0.000 claims abstract description 6
125000001424 substituent group Chemical group 0.000 claims abstract description 5
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims abstract description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 2
-1 thiazole-2,5-diyl Chemical group 0.000 claims description 129
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 58
229960002989 glutamic acid Drugs 0.000 claims description 39
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 34
150000003246 quinazolines Chemical class 0.000 claims description 30
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 29
125000006239 protecting group Chemical group 0.000 claims description 29
239000000460 chlorine Chemical group 0.000 claims description 25
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 24
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 23
229910052801 chlorine Inorganic materials 0.000 claims description 23
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 16
229960003136 leucine Drugs 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 12
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
230000002401 inhibitory effect Effects 0.000 claims description 12
229960004295 valine Drugs 0.000 claims description 12
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 claims description 11
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 11
125000004432 carbon atom Chemical group C* 0.000 claims description 11
125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 10
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 9
238000006243 chemical reaction Methods 0.000 claims description 9
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims description 7
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims description 7
125000001309 chloro group Chemical group Cl* 0.000 claims description 7
150000002367 halogens Chemical group 0.000 claims description 7
XMSZANIMCDLNKA-UHFFFAOYSA-N methyl hypofluorite Chemical group COF XMSZANIMCDLNKA-UHFFFAOYSA-N 0.000 claims description 7
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims description 6
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
229910052794 bromium Chemical group 0.000 claims description 6
125000001153 fluoro group Chemical group F* 0.000 claims description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 claims description 5
QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 claims description 5
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
229930182844 L-isoleucine Natural products 0.000 claims description 5
229960000310 isoleucine Drugs 0.000 claims description 5
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
239000004395 L-leucine Substances 0.000 claims description 4
235000019454 L-leucine Nutrition 0.000 claims description 4
241001465754 Metazoa Species 0.000 claims description 4
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 4
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
239000011737 fluorine Chemical group 0.000 claims description 4
229910052731 fluorine Inorganic materials 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
229960003104 ornithine Drugs 0.000 claims description 4
HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 claims description 3
QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 3
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 claims description 3
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 claims description 3
125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims description 3
239000004471 Glycine Substances 0.000 claims description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
229960003767 alanine Drugs 0.000 claims description 3
125000003277 amino group Chemical group 0.000 claims description 3
229960005261 aspartic acid Drugs 0.000 claims description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
125000001188 haloalkyl group Chemical group 0.000 claims description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
229960001153 serine Drugs 0.000 claims description 3
OJWYYSVOSNWCCE-UHFFFAOYSA-N 2-methoxyethyl hypofluorite Chemical group COCCOF OJWYYSVOSNWCCE-UHFFFAOYSA-N 0.000 claims description 2
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 2
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
206010028980 Neoplasm Diseases 0.000 claims description 2
150000001370 alpha-amino acid derivatives Chemical class 0.000 claims description 2
235000008206 alpha-amino acids Nutrition 0.000 claims description 2
235000003704 aspartic acid Nutrition 0.000 claims description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
125000004181 carboxyalkyl group Chemical group 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
229960002449 glycine Drugs 0.000 claims description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
241000700199 Cavia porcellus Species 0.000 claims 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
125000001246 bromo group Chemical group Br* 0.000 claims 1
230000005907 cancer growth Effects 0.000 claims 1
229960005190 phenylalanine Drugs 0.000 claims 1
125000001544 thienyl group Chemical group 0.000 claims 1
125000003118 aryl group Chemical group 0.000 abstract description 9
230000000259 anti-tumor effect Effects 0.000 abstract description 8
230000000694 effects Effects 0.000 abstract description 4
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 abstract description 4
150000001413 amino acids Chemical class 0.000 abstract description 3
125000004414 alkyl thio group Chemical group 0.000 abstract 3
125000000547 substituted alkyl group Chemical group 0.000 abstract 3
125000005843 halogen group Chemical group 0.000 abstract 2
125000003282 alkyl amino group Chemical group 0.000 abstract 1
125000003710 aryl alkyl group Chemical group 0.000 abstract 1
125000005110 aryl thio group Chemical group 0.000 abstract 1
125000004104 aryloxy group Chemical group 0.000 abstract 1
125000001589 carboacyl group Chemical group 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000004663 dialkyl amino group Chemical group 0.000 abstract 1
125000004957 naphthylene group Chemical group 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
239000000203 mixture Substances 0.000 description 56
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
239000007858 starting material Substances 0.000 description 20
239000000243 solution Substances 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
239000000047 product Substances 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
229910052799 carbon Inorganic materials 0.000 description 10
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
229910052757 nitrogen Inorganic materials 0.000 description 10
238000002360 preparation method Methods 0.000 description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
238000004587 chromatography analysis Methods 0.000 description 9
238000000921 elemental analysis Methods 0.000 description 9
239000000741 silica gel Substances 0.000 description 9
229910002027 silica gel Inorganic materials 0.000 description 9
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
239000003480 eluent Substances 0.000 description 8
239000007787 solid Substances 0.000 description 8
150000002500 ions Chemical class 0.000 description 7
LTKHPMDRMUCUEB-IBGZPJMESA-N CB3717 Chemical compound C=1C=C2NC(N)=NC(=O)C2=CC=1CN(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 LTKHPMDRMUCUEB-IBGZPJMESA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
108010022394 Threonine synthase Proteins 0.000 description 5
102000005497 Thymidylate Synthase Human genes 0.000 description 5
229910052786 argon Inorganic materials 0.000 description 5
239000012298 atmosphere Substances 0.000 description 5
238000001819 mass spectrum Methods 0.000 description 5
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
SFZBYGKTIXYQJL-UHFFFAOYSA-N 2,5,6-trimethyl-1h-quinazolin-4-one Chemical compound N1=C(C)NC(=O)C2=C(C)C(C)=CC=C21 SFZBYGKTIXYQJL-UHFFFAOYSA-N 0.000 description 4
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 4
SXUFSRWTAMNEOE-UHFFFAOYSA-N 6-(bromomethyl)-2,7-dimethyl-1h-quinazolin-4-one Chemical compound CC1=C(CBr)C=C2C(=O)NC(C)=NC2=C1 SXUFSRWTAMNEOE-UHFFFAOYSA-N 0.000 description 4
229930195714 L-glutamate Natural products 0.000 description 4
FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 4
239000002585 base Substances 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
229910052943 magnesium sulfate Inorganic materials 0.000 description 4
235000019341 magnesium sulphate Nutrition 0.000 description 4
238000004949 mass spectrometry Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
239000002904 solvent Substances 0.000 description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 3
IYXDHEMESXAUAD-UHFFFAOYSA-N 6-(bromomethyl)-1h-quinazolin-2-one Chemical compound N1C(=O)N=CC2=CC(CBr)=CC=C21 IYXDHEMESXAUAD-UHFFFAOYSA-N 0.000 description 3
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
WSEQLMQNPBNMSL-FJXQXJEOSA-N diethyl (2s)-2-aminopentanedioate;hydron;chloride Chemical compound Cl.CCOC(=O)CC[C@H](N)C(=O)OCC WSEQLMQNPBNMSL-FJXQXJEOSA-N 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
230000032050 esterification Effects 0.000 description 3
238000005886 esterification reaction Methods 0.000 description 3
239000000284 extract Substances 0.000 description 3
UAOIEEWQVAXCFY-UHFFFAOYSA-N n-(3,4-dimethylphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(C)C(C)=C1 UAOIEEWQVAXCFY-UHFFFAOYSA-N 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
125000005999 2-bromoethyl group Chemical group 0.000 description 2
125000005449 2-fluoro-1,4-phenylene group Chemical group [H]C1=C([*:2])C([H])=C(F)C([*:1])=C1[H] 0.000 description 2
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
239000004342 Benzoyl peroxide Substances 0.000 description 2
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
KJWNDFSDOJWSMV-UHFFFAOYSA-N [6-(bromomethyl)-2,8-dimethyl-4-oxoquinazolin-3-yl]methyl 2,2-dimethylpropanoate Chemical compound N1=C(C)N(COC(=O)C(C)(C)C)C(=O)C2=C1C(C)=CC(CBr)=C2 KJWNDFSDOJWSMV-UHFFFAOYSA-N 0.000 description 2
229960001413 acetanilide Drugs 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
150000001540 azides Chemical class 0.000 description 2
235000019400 benzoyl peroxide Nutrition 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
WBYNXAAEBPJETG-AWEZNQCLSA-N diethyl (2s)-2-[[4-(methylamino)benzoyl]amino]pentanedioate Chemical compound CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C1=CC=C(NC)C=C1 WBYNXAAEBPJETG-AWEZNQCLSA-N 0.000 description 2
HERPVHLYIHBEFW-ZETCQYMHSA-N diethyl (2s)-2-aminopentanedioate Chemical compound CCOC(=O)CC[C@H](N)C(=O)OCC HERPVHLYIHBEFW-ZETCQYMHSA-N 0.000 description 2
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
229940049906 glutamate Drugs 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
239000005457 ice water Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000011630 iodine Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
PJEIIBXJUDOMAN-UHFFFAOYSA-N n-(2,4-dimethylphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(C)C=C1C PJEIIBXJUDOMAN-UHFFFAOYSA-N 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
238000010992 reflux Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
239000008096 xylene Substances 0.000 description 2
MSCGAGYSOJWFJH-UHFFFAOYSA-N (2,6,8-trimethyl-4-oxoquinazolin-3-yl)methyl 2,2-dimethylpropanoate Chemical compound N1=C(C)N(COC(=O)C(C)(C)C)C(=O)C2=CC(C)=CC(C)=C21 MSCGAGYSOJWFJH-UHFFFAOYSA-N 0.000 description 1
NWZACHOBRMGGPL-GSVOUGTGSA-N (3s)-3-amino-2,2-dimethylbutanedioic acid Chemical group OC(=O)C(C)(C)[C@H](N)C(O)=O NWZACHOBRMGGPL-GSVOUGTGSA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
GWVHVSCMHPKJLX-UHFFFAOYSA-N 2,6,7-trimethyl-1h-quinazolin-4-one Chemical compound N1=C(C)NC(=O)C2=C1C=C(C)C(C)=C2 GWVHVSCMHPKJLX-UHFFFAOYSA-N 0.000 description 1
OWDDZTAFUFXSFM-UHFFFAOYSA-N 2,6,8-trimethyl-1h-quinazolin-4-one Chemical compound N1=C(C)NC(=O)C2=CC(C)=CC(C)=C21 OWDDZTAFUFXSFM-UHFFFAOYSA-N 0.000 description 1
GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
JNCIUFLBNBFHHF-UHFFFAOYSA-N 5-nitro-1,3-thiazole-2-carbonyl chloride Chemical compound [O-][N+](=O)C1=CN=C(C(Cl)=O)S1 JNCIUFLBNBFHHF-UHFFFAOYSA-N 0.000 description 1
KNAAFBMBMBMZHI-UHFFFAOYSA-N 5-nitro-1,3-thiazole-2-carboxylic acid Chemical compound OC(=O)C1=NC=C([N+]([O-])=O)S1 KNAAFBMBMBMZHI-UHFFFAOYSA-N 0.000 description 1
VLKRYKLXPSRWEX-UHFFFAOYSA-N 6-(1-bromoethyl)-2-methyl-1h-quinazolin-4-one Chemical compound N1=C(C)NC(=O)C2=CC(C(Br)C)=CC=C21 VLKRYKLXPSRWEX-UHFFFAOYSA-N 0.000 description 1
YAHALGNQKDVJLJ-UHFFFAOYSA-N 6-(bromomethyl)-2-methyl-1h-quinazolin-4-one Chemical compound BrCC1=CC=C2NC(C)=NC(=O)C2=C1 YAHALGNQKDVJLJ-UHFFFAOYSA-N 0.000 description 1
QTIZTQIKKKOUNU-UHFFFAOYSA-N 6-(bromomethyl)quinazoline Chemical compound N1=CN=CC2=CC(CBr)=CC=C21 QTIZTQIKKKOUNU-UHFFFAOYSA-N 0.000 description 1
KGVDNRBJPGFVFW-UHFFFAOYSA-N 6-ethyl-2-methyl-1h-quinazolin-4-one Chemical compound N1=C(C)NC(=O)C2=CC(CC)=CC=C21 KGVDNRBJPGFVFW-UHFFFAOYSA-N 0.000 description 1
KPNNFVSEAVSJBC-UHFFFAOYSA-N 7-methoxy-2,6-dimethyl-1h-quinazolin-4-one Chemical compound N1=C(C)NC(=O)C2=C1C=C(OC)C(C)=C2 KPNNFVSEAVSJBC-UHFFFAOYSA-N 0.000 description 1
FCSPPYQJHGXKDZ-UHFFFAOYSA-N 8-chloro-2,6-dimethyl-1h-quinazolin-4-one Chemical compound N1=C(C)NC(=O)C2=CC(C)=CC(Cl)=C21 FCSPPYQJHGXKDZ-UHFFFAOYSA-N 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
101150065749 Churc1 gene Proteins 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
102100038239 Protein Churchill Human genes 0.000 description 1
101000916532 Rattus norvegicus Zinc finger and BTB domain-containing protein 38 Proteins 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
ISWNXNKBNIVAPX-UHFFFAOYSA-N [6,8-bis(bromomethyl)-4-oxoquinazolin-3-yl]methyl 2,2-dimethylpropanoate Chemical compound C1=C(CBr)C=C2C(=O)N(COC(=O)C(C)(C)C)C=NC2=C1CBr ISWNXNKBNIVAPX-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000001263 acyl chlorides Chemical class 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
CWBHKBKGKCDGDM-UHFFFAOYSA-N bis[(2,2,2-trifluoroacetyl)oxy]boranyl 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OB(OC(=O)C(F)(F)F)OC(=O)C(F)(F)F CWBHKBKGKCDGDM-UHFFFAOYSA-N 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
RJXFBLRRPYBPTM-ZDUSSCGKSA-N diethyl (2s)-2-[(4-aminobenzoyl)amino]pentanedioate Chemical compound CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C1=CC=C(N)C=C1 RJXFBLRRPYBPTM-ZDUSSCGKSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
BQIVJVAZDJHDJF-LURJTMIESA-N ethyl (2s)-2-amino-3-methylbutanoate Chemical compound CCOC(=O)[C@@H](N)C(C)C BQIVJVAZDJHDJF-LURJTMIESA-N 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
239000003607 modifier Substances 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
PSGFNVAAKYVOAT-UHFFFAOYSA-N n-(2-chloro-4-methylphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(C)C=C1Cl PSGFNVAAKYVOAT-UHFFFAOYSA-N 0.000 description 1
HOPWGOFWAPWHDS-UHFFFAOYSA-N n-(4-ethylphenyl)acetamide Chemical compound CCC1=CC=C(NC(C)=O)C=C1 HOPWGOFWAPWHDS-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940127075 other antimetabolite Drugs 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK168488A 1987-03-25 1988-03-25 4-oxo-6-aminomethyl-quinazolinderivater,fremgangsmaade til fremstilling deraf, farmaceutiske midler indeholdende disse samt anvendelse af disse til fremstilling af laegemidler til behandling af tumorer DK167013B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB878707053A GB8707053D0 (en)	1987-03-25	1987-03-25	Anti-tumour agents
GB8707053		1987-03-25

Publications (3)

Publication Number	Publication Date
DK168488D0 DK168488D0 (da)	1988-03-25
DK168488A DK168488A (da)	1988-09-26
DK167013B1 true DK167013B1 (da)	1993-08-16

Family

ID=10614570

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK168488A DK167013B1 (da)	1987-03-25	1988-03-25	4-oxo-6-aminomethyl-quinazolinderivater,fremgangsmaade til fremstilling deraf, farmaceutiske midler indeholdende disse samt anvendelse af disse til fremstilling af laegemidler til behandling af tumorer

Country Status (17)

Country	Link
US (1)	US4981856A (pt)
EP (1)	EP0284338B1 (pt)
JP (1)	JP2577036B2 (pt)
AT (1)	ATE98956T1 (pt)
AU (1)	AU600105B2 (pt)
CA (1)	CA1301756C (pt)
DE (1)	DE3886435T2 (pt)
DK (1)	DK167013B1 (pt)
ES (1)	ES2061641T3 (pt)
FI (1)	FI881340A7 (pt)
GB (2)	GB8707053D0 (pt)
GR (1)	GR3010208T3 (pt)
IL (1)	IL85696A (pt)
NO (1)	NO881300L (pt)
NZ (1)	NZ224010A (pt)
PT (1)	PT87074B (pt)
ZA (1)	ZA881885B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8727737D0 (en) *	1987-11-26	1987-12-31	Ici Plc	Antitumour agents
GB8809978D0 (en) *	1988-04-27	1988-06-02	Ici Plc	Anti-tumour agents
EP0365763A1 (en) *	1988-09-30	1990-05-02	Agouron Pharmaceuticals, Inc.	Antiproliferative cyclic compounds
US5252573A (en) *	1988-12-15	1993-10-12	Imperial Chemical Industries Plc	Anti-tumor agents
GB8829296D0 (en) *	1988-12-15	1989-01-25	Ici Plc	Anti-tumour compounds
US5160727A (en) *	1990-02-13	1992-11-03	Warner-Lambert Company	Tumor cell sensitization method using quinazolinedione derivatives
IL98167A0 (en) *	1990-05-30	1992-06-21	Ici Plc	Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
GB9013615D0 (en) *	1990-06-19	1990-08-08	Wellcome Found	Pharmaceutical compounds
GB9105771D0 (en) *	1991-03-19	1991-05-01	Cancer Res Inst Royal	Anti-cancer compounds
US5145854A (en) *	1991-11-27	1992-09-08	Nair Madhavan G	1-formyl-5,8,10-trideazafolates
GB9205320D0 (en) *	1992-03-11	1992-04-22	Ici Plc	Anti-tumour compounds
GB9205907D0 (en) *	1992-03-18	1992-04-29	Cancer Res Inst Royal	Anti-cancer compounds
US5430148A (en) *	1992-03-31	1995-07-04	Agouron Pharmaceuticals, Inc.	Antiproliferative quinazolines
GB9223352D0 (en) *	1992-11-06	1992-12-23	Ici Plc	Tricyclic compounds
DE4421884A1 (de)	1994-06-23	1996-01-04	Hoechst Ag	Verfahren zur Herstellung von Hydroxycarbonsäureaniliden
DE4427837A1 (de)	1994-08-05	1996-02-08	Hoechst Ag	Verfahren zur Herstellung von O-Acylglykolsäureaniliden
DE19504225A1 (de)	1995-02-09	1996-08-14	Hoechst Ag	Verfahren zur Herstellung von O-Acyloxycarbonsäureaniliden
US5739330A (en) *	1996-02-05	1998-04-14	Hoechst Celanese Corporation	Process for preparing quinazolones
GB9904275D0 (en)	1999-02-24	1999-04-21	Cancer Res Campaign Tech	Anti-cancer compounds
US7230000B1 (en)	1999-10-27	2007-06-12	Cytokinetics, Incorporated	Methods and compositions utilizing quinazolinones
US6545004B1 (en)	1999-10-27	2003-04-08	Cytokinetics, Inc.	Methods and compositions utilizing quinazolinones
US6753428B2 (en) *	2001-11-20	2004-06-22	Cytokinetics, Inc.	Process for the racemization of chiral quinazolinones
WO2003054155A2 (en)	2001-12-19	2003-07-03	Bristol-Myers Squibb Company	Pichia pastoris formate dehydrogenase and uses therefor
AU2003213092A1 (en) *	2002-02-15	2003-09-09	Smithkline Beecham Corporation	Syntheses of quinazolinones
KR20050036911A (ko) *	2002-05-09	2005-04-20	싸이토키네틱스, 인코포레이티드	화합물들, 방법 및 조성물
WO2003097053A1 (en)	2002-05-09	2003-11-27	Cytokinetics, Inc.	Compounds, compositions, and methods
JP2005536475A (ja)	2002-05-23	2005-12-02	サイトキネティクス・インコーポレーテッド	化合物、組成物、および方法
WO2003106426A1 (en) *	2002-06-14	2003-12-24	Cytokinetics, Inc.	Compounds, compositions, and methods
EP1537089A4 (en) *	2002-07-23	2008-04-16	Cytokinetics Inc	CONNECTIONS, COMPOSITIONS AND PROCEDURES
AU2003262747A1 (en) *	2002-08-21	2004-03-11	Cytokinetics, Inc.	Compounds, compositions, and methods
AU2003277079A1 (en) *	2002-09-30	2004-05-04	Cytokinetics, Inc.	Compounds, compositions, and methods
GB0317631D0 (en) *	2003-07-28	2003-08-27	Btg Int Ltd	Synthetic method
EP1682534A2 (en) *	2003-11-03	2006-07-26	Cytokinetics, Inc.	Pyrimidin-4-one compounds, compositions, and methods
WO2005046588A2 (en) *	2003-11-07	2005-05-26	Cytokinetics, Inc.	Compounds, compositions, and methods
WO2005061460A1 (en) *	2003-12-08	2005-07-07	Cytokinetics, Inc.	Compounds, compositions, and methods
BRPI0813355A2 (pt) *	2007-06-22	2014-12-30	Arqule Inc	Compostos de quinazolinona e métodos de uso dos mesmos
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CN105793255B (zh)	2013-10-04	2018-11-16	无限药品股份有限公司	杂环化合物及其用途
MX382033B (es)	2014-03-19	2025-03-13	Infinity Pharmaceuticals Inc	Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US10160761B2 (en)	2015-09-14	2018-12-25	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0031237B1 (en) *	1979-12-19	1984-10-17	National Research Development Corporation	Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
GB8513754D0 (en) *	1985-05-31	1985-07-03	Jones T R	Anti-cancer quinazoline derivatives
GB8607683D0 (en) *	1986-03-27	1986-04-30	Ici Plc	Anti-tumor agents

1987
- 1987-03-25 GB GB878707053A patent/GB8707053D0/en active Pending
1988
- 1988-03-10 IL IL85696A patent/IL85696A/xx not_active IP Right Cessation
- 1988-03-14 GB GB8805982A patent/GB2202847B/en not_active Expired - Lifetime
- 1988-03-16 ZA ZA881885A patent/ZA881885B/xx unknown
- 1988-03-18 AU AU13279/88A patent/AU600105B2/en not_active Ceased
- 1988-03-21 FI FI881340A patent/FI881340A7/fi not_active IP Right Cessation
- 1988-03-22 ES ES88302486T patent/ES2061641T3/es not_active Expired - Lifetime
- 1988-03-22 AT AT88302486T patent/ATE98956T1/de not_active IP Right Cessation
- 1988-03-22 DE DE88302486T patent/DE3886435T2/de not_active Expired - Fee Related
- 1988-03-22 EP EP88302486A patent/EP0284338B1/en not_active Expired - Lifetime
- 1988-03-24 CA CA000562300A patent/CA1301756C/en not_active Expired - Lifetime
- 1988-03-24 NO NO881300A patent/NO881300L/no unknown
- 1988-03-24 NZ NZ224010A patent/NZ224010A/en unknown
- 1988-03-24 PT PT87074A patent/PT87074B/pt active IP Right Grant
- 1988-03-25 DK DK168488A patent/DK167013B1/da not_active IP Right Cessation
- 1988-03-25 JP JP63069943A patent/JP2577036B2/ja not_active Expired - Fee Related
1990
- 1990-04-12 US US07/508,528 patent/US4981856A/en not_active Expired - Lifetime
1993
- 1993-12-23 GR GR920402608T patent/GR3010208T3/el unknown

Also Published As

Publication number	Publication date
US4981856A (en)	1991-01-01
EP0284338B1 (en)	1993-12-22
FI881340A7 (fi)	1988-09-26
EP0284338A3 (en)	1989-05-17
NO881300D0 (no)	1988-03-24
DE3886435T2 (de)	1994-04-14
GR3010208T3 (pt)	1994-03-31
NZ224010A (en)	1990-12-21
GB8707053D0 (en)	1987-04-29
JPS63255270A (ja)	1988-10-21
DE3886435D1 (de)	1994-02-03
ATE98956T1 (de)	1994-01-15
AU1327988A (en)	1988-09-29
FI881340A0 (fi)	1988-03-21
AU600105B2 (en)	1990-08-02
GB2202847B (en)	1990-06-06
PT87074A (pt)	1988-04-01
EP0284338A2 (en)	1988-09-28
JP2577036B2 (ja)	1997-01-29
GB2202847A (en)	1988-10-05
DK168488D0 (da)	1988-03-25
DK168488A (da)	1988-09-26
CA1301756C (en)	1992-05-26
NO881300L (no)	1988-09-26
IL85696A (en)	1993-05-13
PT87074B (pt)	1992-07-31
ZA881885B (en)	1988-09-26
ES2061641T3 (es)	1994-12-16
GB8805982D0 (en)	1988-04-13

Publication	Publication Date	Title
DK167013B1 (da)	1993-08-16	4-oxo-6-aminomethyl-quinazolinderivater,fremgangsmaade til fremstilling deraf, farmaceutiske midler indeholdende disse samt anvendelse af disse til fremstilling af laegemidler til behandling af tumorer
DK166621B1 (da)	1993-06-21	4-oxo-6-aminomethyl-quinazolinderivater, fremgangsmaade til fremstilling heraf, farmaceutisk middel omfattende dem og anvendelse af dem til fremstilling af laegemidler til behandling af tumorer
US5187167A (en)	1993-02-16	Pharmaceutical compositions comprising quinazolin-4-one derivatives
Marsham et al.	1991	Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications
KR100221011B1 (ko)	1999-09-15	항-종양 화합물, 이의 제조 방법 및 이를 함유하는 약학 조성물
US5444061A (en)	1995-08-22	Anti-cancer compounds
EP0318225B1 (en)	1994-03-16	6-Aryl aminomethyl quinoline derivatives and their use as anti-tumour agents
US5561133A (en)	1996-10-01	Thymidylate synthase inhibiting quinazolinones
EA000897B1 (ru)	2000-06-26	ПРОИЗВОДНЫЕ ПИРИДО[2,3-d]ПИРИМИДИНА И ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ИНГИБИРУЮЩЕЙ ПРОТЕИН-ТИРОЗИН-КИНАЗУ АКТИВНОСТЬЮ, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ КЛЕТОЧНОЙ ПРОЛИФЕРАЦИЕЙ, И СПОСОБ ЛЕЧЕНИЯ РАКА, АТЕРОСКЛЕРОЗА, ПСОРИАЗА ИЛИ РЕСТЕНОЗА
EP0469156B1 (en)	1996-10-23	Glutathione derivative
GB2217709A (en)	1989-11-01	Anti-tumour 4-oxoquinazolines
US20070105784A1 (en)	2007-05-10	Substituted quinolines for the treatment of cancer
DK165789B (da)	1993-01-18	4-oxo-4h-pyrimidooe2,1,aaaisoquinolinderivater, analogifremgangsmaade til fremstilling deraf, farmaceutisk praeparat indeholdende disse samt derivaterne til anvendelse som antiallergisk middel

Legal Events

Date	Code	Title
1993-08-16	B1	Patent granted (law 1993)
1994-04-05	B1	Patent granted (law 1993)
1995-11-27	PBP	Patent lapsed